期刊文献+

单克隆抗体人源化的进展及应用 被引量:5

在线阅读 下载PDF
导出
摘要 鼠源性单克隆抗体由于可引起免疫反应而逐渐被人源化抗体所代替,本文介绍了几种人源化抗体构建的策略和表达系统以及人源化抗体在临床方面的应用。
出处 《中国生物制品学杂志》 CAS CSCD 2008年第1期70-73,共4页 Chinese Journal of Biologicals
基金 吉林省科技发展计划重点项目(20060929)
  • 相关文献

参考文献35

  • 1沈倍奋.抗体药物研究进展[J].第二军医大学学报,2002,23(10):1047-1049. 被引量:17
  • 2姜倩倩,刘京贞,苏瑞强.单克隆抗体药物进展[J].药物生物技术,2005,12(4):270-274. 被引量:12
  • 3http://www.pharmtec.org. cn/allpage/newsAll/content 1.
  • 4Kashmiri SVS, De Pascalis R, Gonzales NR, et al. SDR grafting-a new approach to antibody humanization. Humanized Antibodies and Their Applications,2005 ,36( 1 ) :25-34.
  • 5罗萍,邹全明,毛旭虎.治疗性单克隆抗体研究进展及临床应用现状[J].第三军医大学学报,2004,26(5):454-456. 被引量:6
  • 6Higo-Moriguchi K, Akahori Y,Iba Y, et al. Isolation of human monoclonal antibodies that neutralize human rotavirus. J Virol, 2004, 78 (7):3325-3332.
  • 7He MY,Taussig MJ. Ribosome display: cell-free protein display technology. Brief Funt Genomic Proteomic,2002,1 (2) :204-212.
  • 8Green LL. Antibody engineering via genetic engineering of the mouse: Xeno Mouse strains are a vehicle for the facile generation of therapeutic human moloclonal antibodies. J Immunol Methods, 1999,231 (1-2) : 11-23.
  • 9Neuberger M. Generating high-avidity human Mabs in mice. Nat Biotechnol, 1996,14(7) :826-827.
  • 10Yang XD, Corvalan JR, Wang P et al. Fully human anti-interlukin8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states.J leukocyte Biol, 1999,66(3):401-410.

二级参考文献47

  • 1董志伟.第四届国际抗体工程会议简介[J].生命的化学,1994,14(4):16-18. 被引量:3
  • 2Biotechnol News,2001;21(16):6
  • 3Biotechnol News,2000;20(22):3-5
  • 4Biotechnol News,2000;20(23):4-7
  • 5李彪,国外医学放射医学核医学分册,1996年,20卷,151页
  • 6朱承谟,中华核医学杂志,1996年,16卷,75页
  • 7Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors[J]. Br J Cancer, 2001, 85(4) :584-589.
  • 8Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type Ⅰ protein kinase A antisense oligonucleotide[J]. Clin Cancer Res, 2000, 6( 11 ) :4343-4350.
  • 9Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor -targeted therapy with C225 and cisplatin in patients with head and neck cancer [J]. Clin Cancer Res, 2001,7(5) :1204-1213.
  • 10Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J]. J Clin Oncol. 2004, 22(7) :1201-1208.

共引文献71

同被引文献87

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部